Company intelligence / Profile preview

Enzolytics, Inc.

Plano, Texas, United Statesenzolytics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Enzolytics has demonstrated clinical efficacy with its patented anti-HIV therapeutic ITV‑1 and continues to advance multiple preclinical programs using its proprietary fully human mAb technology against various infectious diseases. The company’s approach leverages AI to identify immutable viral targets and produce broadly neutralizing antibodies.

Therapeutic areas: Infectious Diseases
Modalities: Fully human monoclonal antibodies (mAbs)Proprietary proteins (e.g., Inactivated Pepsin Fraction/IPF)Immune therapeutics/vaccines
Industry: Biotech

Drug pipeline

3 assets

Pepsin

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Enzolytics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzolytics, Inc..

Explore the full profile